Theme 11. New therapies and clinical trials

**P5** - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnestic type

**P11** - 11β-hydroxysteroid dehydrogenase type 1 inhibitors pharmacological mechanism of potential therapeutic uses-a systematic review
Sarah Gregory1, John W. Ketelbey2, Tamara Miller2, Vincent Ruffles2, Craig W. Ritchie1
1University of Edinburgh, Edinburgh, UK, 2Actionen Medical Ltd, Sydney, New South Wales, Australia

**P20** - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer’s disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimer’s Disease
Ramachrishna Nirogi, PhD1, Jyothsna Ravula, MS1, Satish Jetta, MS1, Koteswara Mudigonda, PhD1, Vinod Kumar Goyal, MS1, Santosh Kumar Pandey, MS1, Gopinadh Bhyrapuneni, PhD1, Renny Abraham, PhD1, Vijay Benade, MS1, Pradeep Jayarajan, PhD1, Anil Shinde, PhD1, John Ieni, PhD1 and Venkat Jasti, MS1
1Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**P23** - Efficacy and safety of trigriluzole (BHV-4157) in patients with mild to moderate Alzheimer’s dementia: T2 PROTECT AD phase 2 study design
Irfan A. Qureshi, M.D.1, Karen Meszer, Ph.D.2, Kirsten Erichson, Ph.D.2, Robert M. Berman, M.D.1, Carolyn Revta2, Timlan Oltersdorf, M.D.2, Branko Huia, M.D.2, Diane Jacobs, Ph.D.2, David Salmon, Ph.D.2, Doug Galasko, M.D.2, Thomas O. Obisesan, M.D.3, Neelum Aggarwal, M.D.4, Jacobo Mintzer, M.D.4, Judith Heidebrink, M.D.5, Amanda Smith, M.D.5, Miranda N. Reed, Ph.D.5, Holly C. Hunsberger, Ph.D.5, Lia Donahue1, Kimberly Gentile1, David A. Stock, Ph.D.1, Vladimir Coric, M.D.1, Howard Feldman, M.D.2
1AstraZeneca R&D, Macclesfield, UK, 2Howard University, Washington, DC, USA, 3University of San Francisco, San Francisco, CA, USA, 4University of Michigan, Ann Arbor, MI, USA, 5University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, 6Auburn University, Auburn, AL, USA

**P56** - Gamma-secretase modulation has multiple anti-amyloidogenic effects in vivo
Benot Winblad1, Gunnar Nordvall1, Ping Yan3, Johan Lundqvist2, Johan Sandin2,3, Henrik Biverstål1, Henrik Zetterberg1, Rebeca Klimentberg1, Mats Ferm1, John R Cirrito3, Jin-Moo Lee3
1AlzCare Pharma AB, Drug Discovery & Development, Huddinge, Sweden, 2AlzCare Foundation, Preclinical Research, Huddinge, Sweden, 3AstraZeneca R&D, CNS & Pain Med, Södertälje, Sweden, 4Karolinska Institutet, Dept Unit, Div of Neurogenetics, Sorin, Sweden, 5Washington University School of Medicine, Dept of Neurology, St Louis, USA, 6Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, 7Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Möln达尔, Sweden

**P60** - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer’s disease
Rainish Kumar, PhD1, Pavol Pavlov, PhD1, Bengt Winblad, MD, PhD2
1Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Solna, Sweden, 2Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

**P79** - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice
Francois J. Roman1, PhD1, Johann Meunier1, PhD1, Laura Ceolin1, PhD1, Jean-Marie Butterlin2, MS1, Guillaume Blivet3, MS, Jacques Touchon5, MD, PhD
1Amylgen, Montpellier-sur-Lez, France, 2Health Optimization Devices B.V, Maastricht, Netherlands, www.cognixtra.com, 3Montpellier, France, 4INSERM U1061 & Montpellier University, Montpellier, France

**P84** - Clinical Development of AXS-05 (Dextromethorphan/Buproprion) for Agitation Associated with Alzheimer’s Disease
Henriot Tabuteau, MD1, Amanda Jones, PharmD2, Cedric O’Gorman, MD1
1Awesome Therapeutics Inc, USA

**P85** - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer’s disease
Gerson D. Hernandez, MD, MPH1, Naoto Kono, MPH1, Claudia M. Lopez, BS1, Ron Irwin, PhD1, Kathleen Rodgers, PhD1, Jimmy Wu, PhD1, Rosario Molto, PhD1, Sonia Pawluczyn, MD1, Meng Law, MD1, Wenda Mach, PhD2, Lon Schneider, MD, MS1, Roberta D. Brinton, PhD1
1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, 2Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA, 4TOMO Pharmacometrics, LLC, San Mateo, USA, 5Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
PI05 - SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease
Benoît Melchior, PhD1, Carolyn Lai1, Karen Duong-Polk1, Amanda Tjitro1, Lauren Pitzer1, Joshua Stewart1, Luis Dellamary1, Scott Anderson1, Brian Hofilena1, Chiao-Wen Chen, PhD2, Charlene Barroga, PhD2, Gopi Mittapalli, PhD2, Sunil KC, PhD2, Philippe Marchand, PhD1, and Yusuf Yazici, MD1
Samumed, LLC, San Diego, USA

PI06 - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease
Ewelina Kulikowska1, Emily Daze1, Sylwia Wasiak1, Dean Gilham1, Laura M. Tsujikawa1, Brooke Rakai1, Stephanie C. Stotz1, Christopher Halliday1, Ravi Jahagirdar1, Norman C. W. Wong1, Michael Sweeney1 and Jan O. Johansson2
1Resverlogix Corp, Calgary, AB, Canada; 2Resverlogix Inc, San Francisco, CA, USA

PI07 - Clinical radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy
Fabrizio Piazza, PhD23*, on behalf of The iCAβ International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia*; Jacopo C. DiFrancesco23, Marialuisa Zedde15, Federica Angiulli13, Rosario Pascarella15, Roberto Marconi15, Francesco Perini15, Alberto Villarejo-Galende15, Mario Cirillo15, Berardino Orlandi15, Ibara Masafumi15, Mehdi Touati15, Hagiwara Yuta16, Juan F. Vázquez-Costa15, Massimo Caulo15, Shima Atsushi16, Alessia Giossi18, Ricardo Nitrini18, Massimo Musicco18
*Main Network Collaborators:
1The inflammatory cerebral amyloid angiopathy and Alzheimer’s disease Biomarkers (iCAβ) International Network, University of Milano Bicocca, Monza, Italy, 2University of Milano Bicocca, Monza, Italy, 3National Research Council, Segrate, Italy, 4Arcispedale Santa Maria Nuova-Irccs, Reggio Emilia, Italy, 5Department of Neuroscience, Ospedale Misericordia, Grosseto, Italy, 6St. Borolo Hospital, Vicenza, Italy, 7Hospital 12 de Octubre. CIBERNED, Madrid, Spain, 8Università della Campania “Luigi Vanvitelli”, Seconda Università degli Studi di Napoli, Italy, 9S. Filippo and Nicolò Hospital in Avezzano, L’Aquila, Italy, 10National Cerebral and Cardiovascular Center, Osaka, Japan, 11Dana-Farber Brigham and Women’s Hospital, Boston, Massachusetts, Inserm U1027, CNRS UMR 7225, Sorbonne Universités, Paris, France & USA, 12St. Marianna University School of Medicine, Japan, 13Instituto de Investigación Sanitaria La Fe (IS La Fe), Valencia, Spain, 14University «G. d’Annunzio», Chieti, Italy, 15Kyoto University Graduate School of Medicine, Kyoto, Japan, 16“O.U. of Neurology, ASST Cremona, Italy, 17University of São Paulo School of Medicine, São Paulo, Brazil

PI08 - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly CorplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept
Bobby Singh
Corium International, Inc, 235 Constitution Drive, Menlo Park, California, USA